A systematic update to circulating extracellular vesicles proteome; transcriptome and small RNA-ome as glioma diagnostic, prognostic and treatment-response biomarkers

Nikoobakht, Mehdi; Shamshiripour, Parisa; Shahin, Mohadese; Bouzari, Behnaz; Razavi-Hashemi, Melika; Ahmadvand, Davoud; Akbarpour, Mahzad

doi:10.1016/j.ctarc.2021.100490

Cited by 6 publications

(7 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, before translating its use into clinical practice, the mechanisms and pathways of exRNA treatment should be understood. It is still unknown how to introduce this biomarker into clinical disease surveillance ( 10 , 91 , 92 ). Further, interspecies exRNA transfer may occur through contact and feeding, opening a new entry point for the transboundary transfer of exRNA.…”

Section: Conclusion Challenges and Perspectivesmentioning

confidence: 99%

Extracellular RNA as a kind of communication molecule and emerging cancer biomarker

Tao

Eshraghian

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

Extracellular RNA (exRNA) is a special form of RNA in the body. RNA carries information about genes and metabolic regulation in the body, which can reflect the real-time status of cells. This characteristic renders it a biomarker for disease diagnosis, treatment, and prognosis. ExRNA is transported through extracellular vesicles as a signal medium to mediate communication between cells. Tumor cells can release more vesicles than normal cells, thereby promoting tumor development. Depending on its easy detection, the advantages of non-invasive molecular diagnostic technology can be realized. In this systematic review, we present the types, vectors, and biological value of exRNA. We briefly describe new methods of tumor diagnosis and treatment, as well as the difficulties faced in the progress of such research. This review highlights the groundbreaking potential of exRNA as a clinical biomarker.

show abstract

Section: Conclusion Challenges and Perspectivesmentioning

confidence: 99%

Extracellular RNA as a kind of communication molecule and emerging cancer biomarker

Tao

Eshraghian

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Protein exosome markers, important for exosome formations, are tetraspanins CD9, CD63, and CD81 while Alix, TSG101, HSC70, and HSP90β are part of the complexes named endosomal sorting complex required for exosome formation and transport. Although these proteins are thought to be exosomal markers, they can be found or present in other cells and processes [ 27 , 28 , 29 , 30 ]. So far, the markers for microvesicles have not been so well established, but they can carry the tetraspanins CD9, CD63, and CD81, and ARF6 and VCAMP3 have been proposed [ 27 , 29 ].…”

Section: Extracellular Vesicles In Glioblastomamentioning

confidence: 99%

“…Although these proteins are thought to be exosomal markers, they can be found or present in other cells and processes [ 27 , 28 , 29 , 30 ]. So far, the markers for microvesicles have not been so well established, but they can carry the tetraspanins CD9, CD63, and CD81, and ARF6 and VCAMP3 have been proposed [ 27 , 29 ]. Recognized markers for apoptotic bodies are annexin V, thrombospondin, and C3b.…”

Section: Extracellular Vesicles In Glioblastomamentioning

confidence: 99%

“…Membrane molecules can be also oxidized, leading to creation of binding sites for thrombospondin or the complement protein C3b, which are again recognized by phagocytes [ 27 , 30 ]. In the apoptotic bodies also HSP60 from mitochondrial origin or GRP78 from endoplasmic reticulum have been found to be enriched [ 29 ]. Beside interrogation of ‘‘classical’’ markers for EVs, also markers for oncogenic EVs exist.…”

Section: Extracellular Vesicles In Glioblastomamentioning

confidence: 99%

“…As such EGFR, EGFRvIII, GFAP, hTERT, IDH1, and IDH1R132 have been recognized. In recent papers on glioblastoma-derived EVs their cargo and corresponding biological role is elaborated in more detail [ 29 , 31 ].…”

Section: Extracellular Vesicles In Glioblastomamentioning

confidence: 99%

See 2 more Smart Citations

Dynamic Intercell Communication between Glioblastoma and Microenvironment through Extracellular Vesicles

et al. 2022

View full text Add to dashboard Cite

Glioblastoma is simultaneously the most common and most aggressive primary brain tumor in the central nervous system, with poor patient survival and scarce treatment options. Most primary glioblastomas reoccur and evolve radio- and chemoresistant properties which make them resistant to further treatments. Based on gene mutations and expression profiles, glioblastoma is relatively well classified; however, research shows that there is more to glioblastoma biology than that defined solely by its genetic component. Specifically, the overall malignancy of the tumor is also influenced by the dynamic communication to its immediate and distant environment, as important messengers to neighboring cells in the tumor microenvironment extracellular vesicles (EVs) have been identified. EVs and their cargo can modulate the immune microenvironment and other physiological processes, and can interact with the host immune system. They are involved in tumor cell survival and metabolism, tumor initiation, progression, and therapy resistance. However, on the other hand EVs are thought to become an effective treatment alternative, since they can cross the blood–brain barrier, are able of specific cell-targeting and can be loaded with various therapeutic molecules.

show abstract

Survey of organ‐derived small extracellular vesicles and particles (sEVPs) to identify selective protein markers in mouse serum

Abdelmohsen,

Herman,

Carr

et al. 2023

J of Extracellular Bio

View full text Add to dashboard Cite

Extracellular vesicles and particles (EVPs) are secreted by organs across the body into different circulatory systems, including the bloodstream, and reflect pathophysiologic conditions of the organ. However, the heterogeneity of EVPs in the blood makes it challenging to determine their organ of origin. We hypothesized that small (s)EVPs (<100 nm in diameter) in the bloodstream carry distinctive protein signatures associated with each originating organ, and we investigated this possibility by studying the proteomes of sEVPs produced by six major organs (brain, liver, lung, heart, kidney, and fat). We found that each organ contained distinctive sEVP proteins: 68 proteins were preferentially found in brain sEVPs, 194 in liver, 39 in lung, 15 in heart, 29 in kidney, and 33 in fat. Furthermore, we isolated sEVPs from blood and validated the presence of sEVP proteins associated with the brain (DPP6, SYT1, DNM1L), liver (FABPL, ARG1, ASGR1/2), lung (SFPTA), heart (CPT1B), kidney (SLC31), and fat (GDN). We further discovered altered levels of these proteins in serum sEVPs obtained from old mice compared to young mice. In sum, we have cataloged sEVP proteins that can serve as potential biomarkers for organ identification in serum and show differential expression with age.

show abstract

A systematic update to circulating extracellular vesicles proteome; transcriptome and small RNA-ome as glioma diagnostic, prognostic and treatment-response biomarkers

Cited by 6 publications

References 56 publications

Extracellular RNA as a kind of communication molecule and emerging cancer biomarker

Extracellular RNA as a kind of communication molecule and emerging cancer biomarker

Dynamic Intercell Communication between Glioblastoma and Microenvironment through Extracellular Vesicles

Survey of organ‐derived small extracellular vesicles and particles (sEVPs) to identify selective protein markers in mouse serum

Contact Info

Product

Resources

About